Ibrahim Aldoss

المهنة: باحث

سلسلة

There is nothing here

Create a new serie

أعمال

There is nothing here

Create a new work

مقالات 72

Date

العنوان

الكاتبون

2022-09-10

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Monzr M Al Malki, Hoda Z Pourhassan, Vinod Pullarkat, Ibrahim Aldoss
2020-02-05

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Matthew Mei, Ibrahim Aldoss, Ryotaro Nakamura
2020-03-19

The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement

Ibrahim Aldoss
2020-02-28

Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital

Matthew Mei, Ibrahim Aldoss
2020-03-19

Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin

Talha Badar, Aniko Szabo, Mark R Litzow, Ibrahim Aldoss
2020-03-01

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss
2020-03-01

How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia

Ibrahim Aldoss
2020-05-13

Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia

Matthew Mei, Ibrahim Aldoss, Ryotaro Nakamura
2020-05-01

Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab

Mark R Litzow, Ibrahim Aldoss
2020-06-10

Iron Overload is Associated with Delayed Engraftment and Increased Non-Relapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation

Ibrahim Aldoss
2020-07-06

Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia

Ibrahim Aldoss, Monzr M Al Malki, Paul B Koller, Vinod Pullarkat
2020-07-21

Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia

Joo Y Song, Ibrahim Aldoss
2020-08-19

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

Ibrahim Aldoss
2020-09-03

Tumor intrinsic and extrinsic determinants of response to blinatumomab in adults with B-ALL

Ibrahim Aldoss
2020-09-14

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia

Fabio Ciceri, Ibrahim Aldoss
2020-08-28

Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia

Matthew Mei, Ibrahim Aldoss, Ryotaro Nakamura
2020-10-01

Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy

Ibrahim Aldoss
2020-10-01

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Martin Bornhäuser, Ibrahim Aldoss
2020-11-23

Outcomes of Therapy with Venetoclax Combined with A Hypomethylating Agent in Favorable-Risk Acute Myeloid Leukemia

Shukaib Arslan, Vinod Pullarkat, Ibrahim Aldoss
2020-12-01

Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia

Talha Badar, Mehrdad Hefazi, Nikolai Podoltsev, Anand A Patel, Mark R Litzow, Ibrahim Aldoss
2019-01-08

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen

Matthew Mei, Guido Marcucci, Ibrahim Aldoss, Ryotaro Nakamura
2019-04-26

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

Matthew Mei, Guido Marcucci, Dennis D Weisenburger, Ibrahim Aldoss, Ryotaro Nakamura
2019-04-23

Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia

Jeremy Chang, Ibrahim Aldoss
2019-09-16

Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center

Matthew Mei, Ibrahim Aldoss, Ryotaro Nakamura
2019-04-24

Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1

Ibrahim Aldoss
2019-09-01

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

Hong Qin, Zhenyuan Dong, Feng Wen, Weili Xue, Miriam Walter, Fan Fei, Jianming Xie, Theano I Panagopoulou, Chun-Wei Chen, Larry W Kwak, Ibrahim Aldoss
2019-09-26

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Richard Olsson, Sachiko Seo, Nandita Khera, David Rizzieri, Nelson J Chao, Mark R Litzow, Ibrahim Aldoss, Patrick Stiff, Brenda M Sandmaier
2019-01-08

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML

Le Xuan Truong Nguyen, Ibrahim Aldoss
2019-10-01

More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine

Ibrahim Aldoss
2019-01-21

Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment

Ibrahim Aldoss
2019-11-06

Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

Monzr M Al Malki, Matthew Mei, Haris Ali, Ibrahim Aldoss, Ryotaro Nakamura
2019-01-29

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones

Matthew Mei, Ibrahim Aldoss, Ryotaro Nakamura

Human - wd:Q92806124

أهلًا وسهلًا إلى آنڤانتير

مكتبة أصدقائك ومجتمعاتك

تعلم المزيد